Ouch! I’m seeing a drop coming?
$ACADIA Pharmaceuticals (ACAD.US)$ Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effect size=0.07). The safety and tolerability profile of pimavanserin was consistent with previous clinical trials, showing a low rate of adverse events.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Jaguar8 : Again.
Trytosaveabit OP Jaguar8 : Yup! Another that’s probably going to plummet?
Jaguar8 Trytosaveabit OP : Big time plummet. I hope nobody is left bagholding
Trytosaveabit OP Jaguar8 : You and me both! Even if it has a great pipeline with others soon to be reported! These are dangerous plays for just that reason! Some are just a huge overreaction! Some are not though.
Jaguar8 Trytosaveabit OP : It’s like NERV
Trytosaveabit OP Jaguar8 : Yup!